• "Influenza remains one of the most serious public health challenges and new therapeutic and preventative solutions are needed.”
    Hanneke Schuitemaker
    "Influenza remains one of the most serious public health challenges and new therapeutic and preventative solutions are needed.”
    Hanneke Schuitemaker
    Head of Viral Vaccine Discovery and Translational Medicine, Infectious Disease and Vaccines Therapeutic Area, Janssen Pharmaceutical Companies of Johnson & Johnson
  • “The era of engagement, trust, conversation and corporate empathy has arrived.”
    “The era of engagement, trust, conversation and corporate empathy has arrived.”
    Maggie FitzPatrick
    Chief Communication Officer, Johnson & Johnson
  • “My vision is to build the most engaging, consumer-centric, and efficient R&D organization focused on simplicity, differentiated innovation and building on our legacy of disrupting health care to create better health outcomes for people."
    “My vision is to build the most engaging, consumer-centric, and efficient R&D organization focused on simplicity, differentiated innovation and building on our legacy of disrupting health care to create better health outcomes for people."
    Josh Ghaim, Ph.D.
    Chief Technology Officer, Johnson & Johnson Family of Consumer Companies
  • “We at Janssen are committed to building on the work of Dr. Vogelstein, who showed us that the origins of cancer begin many years before the onset of disease and provides us with the tools to intercept cancer before it ever becomes an illness.”
    “We at Janssen are committed to building on the work of Dr. Vogelstein, who showed us that the origins of cancer begin many years before the onset of disease and provides us with the tools to intercept cancer before it ever becomes an illness.”
    William N. Hait, MD
    Global Head, Janssen Research & Development, LLC
  • “As a young physician training in Africa, I confronted a terrifying new enemy — we didn’t even know it was HIV back then. Today, 30 years later, we have figured out a way to keep this enemy at bay, but our work is not done.”
    “As a young physician training in Africa, I confronted a terrifying new enemy — we didn’t even know it was HIV back then. Today, 30 years later, we have figured out a way to keep this enemy at bay, but our work is not done.”
    Paul Stoffels, M.D.
    Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals Johnson & Johnson
  • “We work to bring together various organizations doing great work separately to spark new collaborations that can bring forward further innovations to use data to strengthen health systems.”
    Michael Bzdak, Ph.D.
    “We work to bring together various organizations doing great work separately to spark new collaborations that can bring forward further innovations to use data to strengthen health systems.”
    Michael Bzdak, Ph.D.
    Executive Director of Corporate Contributions Johnson & Johnson
  • “Agility is fundamental to leading a team through times of change. Build an environment that empowers your team to take risks.”
    “Agility is fundamental to leading a team through times of change. Build an environment that empowers your team to take risks.”
    Sandi Peterson
    Group Worldwide Chairman, Member, Executive Committee, Johnson & Johnson
  • “Nothing is more important to us than the safety of consumers and maintaining their trust in our products.”
    Jeff B. Smith
    “Nothing is more important to us than the safety of consumers and maintaining their trust in our products.”
    Jeff B. Smith
    President, U.S. Skincare, Johnson & Johnson Family of Consumer Companies
  • Prevent Hepatitis: Know the Facts
    Prevent Hepatitis: Know the Facts
  • Committed to #MakeHIVstory
    Committed to #MakeHIVstory
  • Janssen HIV - Young Adults and HIV
    Young Adults and HIV
  • Blood Clot And Cancer Connection
    Blood Clot And Cancer Connection
  • Why U.S. Hispanics Require a Tailored Approach to Type 2 Diabetes (T2D) Care
    INVOKANA Hispanic Initiative Survey Results
  • Stop TB Partnership
    Stop TB Partnership
  • Stop TB Partnership: Reach / Global Drug Facility
    Stop TB Partnership: Reach / Global Drug Facility
  • Stop TB Partnership: Global Fund
    Stop TB Partnership: Global Fund
Media Contacts More Photos & Infographics

Working members of the media, please use the following Johnson & Johnson media relations contacts for inquiries. Not a member of the media? No problem. Please visit our Contact Us page for information on sponsorships, charitable contributions, career opportunities, student discounts and more.

  • Ernie Knewitz
    Ernie Knewitz
    Vice President, Global Media Relations
    Office Telephone: +1-732 524-6623
  • Amy Jo Meyer
    Amy Jo Meyer
    Director, Corporate Media Relations
    Office Telephone: +1-732-524-6678